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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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Etiology and relevance 
In Africa and the Arabic Peninsula where it occurs, Rift Valley fever (RVF) is a major animal and public health 
problem, in both endemic and epidemic forms.  It is caused by a mosquito-borne multispecies single stranded 
RVF virus of the Phlebovirus genus in the Bunyaviridae family. This zoonotic disease, with significant socio-
economic impact, is complicated by the fact that major epizootics occur after intervals that can last several 
years, thus finding the countries completely unprepared.  
The disease has a considerable impact on producers including smallholder farmers, traders, the livestock 
industry and public health. The costs of an outbreak can be considerable, for example the cost of the East 
African outbreak in 1997-1998 was estimated at over USD 250 million, and the 2006-2007 outbreak in Somalia 
was estimated at USD 471 million. RVF has also been taken considerable relevance as a potential bioterrorist 
threat.  
 
Epidemiology and transmission 
In endemic regions, the virus is believed to circulate transovarially in mosquito vectors for years, causing often 
unnoticed infections and mild disease, until such time that favourable conditions are present to trigger major 
epidemics. Outbreaks of the disease are associated to the simultaneous presence and circulation of the RVF 
virus by mosquito vectors, the mosquito pressure (number of breeding sites and hatching frequency), which is 
highly dependent on environmental conditions, particularly heavy rainfall events; and the distribution of 
domestic animal hosts, essentially ruminants (goats, sheep and cattle) vulnerable to the increased vector/host 
contacts at night. 
Mosquitoes constitute the major source of transmission of the virus, although in utero transmission to the 
foetus by the dam in ruminants, camels and other susceptible species can occur. The virus may also infect other 
animals exposed to abortion or birth products, which contain large amounts of virus, although the importance of 
this route is still controversial. At present, the major mosquito hosts appear to be members of the genera Aedes, 
Culex and Anopheles. Other biting insects might also be able to transmit this virus from viremic animals, 
although their role (if any) in nature is still uncertain. 
In endemic regions, spontaneous abortions among livestock, especially small ruminants, and high mortality rates 
in new born animals are a hallmark for epidemics of RVF. Between epidemics, this virus can circulate without 
apparent clinical signs in susceptible species, or there may be sporadic abortions that could be confused with 
other diseases. 
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Suspicion of RVF could generally be made when heavy rains are followed by the occurrence of abortions in 
sheep, cattle and goats together with fatal disease, particularly in young and pregnant animals. Frequently there 
is also influenza-like illness in livestock owners. Specimens to be submitted for laboratory confirmation of the 
diagnosis include heparinized or clotted blood, plasma or serum of live affected animals or tissue samples, 
including liver, spleen, kidney, lymph nodes and heart blood of dead animals. Samples from aborted foetuses 
should also be sent. RVF virus can be isolated from blood and the different tissues above. 
 
Control 
Given the long and inconsistent inter-epidemic period and the potential devastating nature of outbreaks, it is 
always recommended that endemic countries institute active and passive surveillance programs, consisting of 
different actions. The purpose of the active surveillance is to demonstrate the presence or absence of RVFV 
antibodies (IgM and IgG) and clinical disease in high risk areas with history of the disease. This is generally done 
through the use of sentinel animals regularly serologically tested, and possibly conducting syndromic 
surveillance focusing on clinical signs.  
For the control of RVF, there is no effective chemotherapy or treatment. Mosquito control although may assist 
in improving the disease situation during outbreaks, is not often effective as a major control tool. Immunisation 
has been so far the most effective control strategy. 
 
Vaccination and vaccination strategies 
To date there are three commercially available vaccines: the inactivated RVF vaccine, produced in South Africa 
and in Egypt, the live attenuated vaccine based on the Smithburn virus strain produced in South Africa and in 
Kenya, and the more recently registered RVF Clone 13, produced in South Africa.  
While the live attenuated RVF Smithburn vaccine has been the most widely used vaccine for many years, it has 
safety shortfalls, including risk of triggering abortion in a small proportion of vaccinated pregnant animals; thus 
is not recommended for use in pregnant animals. The inactivated RVF vaccine, which would have been suitable 
for use even in the middle of an outbreak, requires booster doses, making it impractical for use in most 
vaccination programs in Africa. The RVF Clone 13 was successfully used in the 2008 RVF outbreak in South 
Africa. But due to stability problems with the vaccine, the production of the vaccine has been discontinued. 
The cyclical nature of RVF epidemics and the subsequent long inter-epidemic periods have resulted in many 
countries considering the use of vaccination only when there is the first indication of an outbreak, with negative 
consequences, as the pressure increases on the limited manufacturers to suddenly supply enough vaccines to all 
requesting countries. Alternatively, control strategies that promote the establishment of solid herd immunity in 
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the livestock population in endemic regions are more likely to reduce the devastating impact of severe 
outbreaks. Yearly vaccination, practiced in limited number of countries, such as South Africa, would contribute 
to increased herd immunity. Two strategies have been considered for addressing the issue of vaccine availability 
and improved herd immunity: (1) the RVF vaccine bank (or strategic stock) and (2) use of combination vaccines 
including RVF which would then rely on the regular vaccination of animals for the second, more commonly used 
vaccine, such as Lumpyskin disease in cattle and sheep and goat pox in sheep and goat, in order to build 
immunity in vaccinated animals to RVF.  
 
The future of RVF vaccines and vaccination  
Several research groups around the world have been working on developing new candidate vaccines using 
different strategies. While almost no improvement to the inactivated vaccine approach has been reported, 
despite extensive progress globally on adjuvant technology, RVF vaccine research has seen almost all novel 
technologies been applied to it: reverse genetic to generate deleted viruses, virus like particle, virus-vectored 
vaccines, subunit vaccines, plant expression, combination vaccines etc. Sadly none of these new generation 
vaccines have been developed industrially nor commercialised. 
One of the reasons that have prevented the evaluation of these candidate vaccines in target animal is the 
limited availability of validated challenge models. The zoonotic nature of RVF and the lack of available human 
vaccine have also made it impossible for many research groups in free or endemic countries to conduct target 
animal efficacy or safety studies requiring challenge with virulent viruses.    
A number of key characteristics for the ideal vaccine and target product profile are not necessarily included in 
existing or candidate vaccines developed to date. For new candidates, some of the characteristics such as DIVA, 
safety in all categories, prevention of viremia etc., have not been confirmed due to lack of target animal data. 
The DIVA aspect, not possible in any of the currently commercial vaccines, has not been confirmed on any 
known candidate vaccine due to among other reasons the inability to develop specific serological tests (ELISA) 
based on most of the RVF proteins not present in the candidate vaccine. Subsequent to the above points, the 
way forward with RVF vaccine and vaccination would be an assessment of already developed vaccine candidates 
for their suitability in meeting the key requirements, and on how they could be included in effective vaccination 
strategies. 
A number of critical points are needed to be considered in order to achieve this, and include: 
1. Need to validate an effective challenge model and validate in vitro correlates to protection 
2. Need to assess candidate vaccines that meet theoretically most of the key characteristics of the idea 
vaccine through further target animal studies. The selection of such candidates should also take into 
account the ability for their easy production at industrial scale 
Rift Valley Fever | Monograph 05 






3. For candidate vaccines with a DIVA potential, need to develop and validate their companion 
diagnostic test 
4. Where possible need to develop or include RVF into multivalent vaccines, in order to increase RVF 
vaccine uptake 
5. Need to develop the most suitable vaccination strategies 
The implementation of appropriate vaccination strategies, or control strategies involving RVF vaccines will be 
the best way to improve RVF prevention and control, given the fact that most endemic countries do not 
vaccinate during inter-epidemic periods or around declared epidemics. The strategies should include regional 
approaches relying on tools such as vaccine banks, multi-vaccines, field tools for active surveillance (sentinel 
animals and field diagnostic assays etc.). Pilot programs for the development and consolidation of adapted 
vaccination strategies could be conducted at regional level in Africa (Southern African community region, SADC 
or East African Community, EAC), building on lessons learned to date from partial joint programs. 
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Clinical disease overview 
Etiology 
Rift Valley Fever (RVF) is a mosquito-borne 
multispecies zoonotic disease affecting livestock 
and other species, caused by the RVF virus. 
Following the first description of a disease 
resembling Rift Valley fever (RVF) and affecting 
sheep by Montgommery in Kenya in 1912-13, Rift 
Valley fever was formerly identified in 1930 during 
a major outbreak in a farm near Lake Naivasha in 
Kenya [10]. The virus responsible for this outbreak 
was isolated from blood and liver of infected sheep 
and called Rift Valley fever virus (RVFV). 
A worthwhile noting element for the RVF virus is 
the fact that the NSs is an important virulence 
factor. While RVFV replicates in the cytoplasm, NSs 
is the only viral protein present in the nucleus of 
the host cell where it forms filamentous structures 
[47][56] interacting with several cellular proteins and 
causing various effects responsible for RVFV 
pathogenicity.  
Although different lineages have been described 
for RVF virus, resulting in different manifestation of 
the disease, there is only one serotype of RVFV, 
hence any RVF vaccine protects against all lineages.   
Virus structure 
RVF virus belongs to the Phlebovirus genus of the 
Bunyaviridae family. The RVF virus is enveloped and spherical 
with a diameter of 80-120 nm. Like all the members of the 
family, it possesses a single-stranded tripartite RNA genome 
composed of 3 segments: the large (L), the medium (M), and 
the small (S) segments, as illustrated below and in Figures 2.  
The L segment encodes for the L protein, the M segment is 
the precursor to the glycoproteins GN and GC and the two 
non-structural proteins 78 KDa and 14 KDa; and the S 
segment codes for the N nucleoprotein and the non-
structural NSs protein using an ambisense strategy [16]. The L 
and M segment are of negative sense polarity.  
 
Figure 1: Rift Valley Fever virus structure 
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Figure 2: Rift Valley Fever virus genome segments and replication strategies. Precursor proteins expressed 




Susceptible animal species  
A large number of mammalians are susceptible to RVF, while birds, reptiles and amphibians are refractory. 
Susceptibility varies between species and also with age of animals as illustrated in Table 1 below. Humans are 




To date RVF has only been reoprted on the African continent and the Arabian peninsula. Following the first 
reported outbreak of RVF in Kenya in 1930, the virus remained endemic in the region and caused sporadic 
outbreaks, especially after periods of exceptionally heavy rains. Beside those countries linked to the Great Rift 
Valley formation, which stretch from the Red Sea through East Africa to Madagascar, serious outbreaks of RVF 
have occurred in Egypt, Mauritania and Senegal.  
 
The first human fatalities directly attributable to RVFV infection were reported in South Africa in 1975 [33][52]. 
Abortion of sheep is observed almost systematically during the RVF outbreaks. In Madagascar, RVFV was 
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reported as early as 1978 and in 1990-91 but after a silence of 20 years, the most important emergence 
occurred in 2010.  
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Lambs Sheep Cattle Camels Birds 
Kids Calves Goats Equids Reptiles 
Puppies 
 
African buffalo Pigs Amphibians 
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Certain other rodents 
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Importantly, the virus extended its territory in 2000 causing a major outbreak in Saudi Arabia and Yemen. 
Several other African countries have reported small outbreaks or virus circulation monitored by the presence of 
RVF specific antibodies and in some cases virus isolation. In 2008, the circulation of the virus was reported for 
the first time in the Comoros Islands. Figure 3 shows a map with the countries with endemic RVF, and countries 
at risk.  For additional information see Secion 3.   
 
RVF Transmission 
More than 30 species of mosquitoes are potentially involved in RVFV transmission, the main vectors belonging 
to the Aedes, Culex and Anopheles genera [30][50][45]. It is important to note that the virus has been isolated from 
several insects, including ticks and culicoides. However until now, there is no evidence of the virus ability to 
replicate in these species as laboratory experiments suggest that some of these species are not competent 
vectors for transmission. Potential mechanical and/or biological vectors include stable flies (Stomoxys spp.), 
tsetse flies (Glossina morsitans), sandflies (Lutzomyia longipalpis), biting midges (Culicoides variipennis), 
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blackflies and ticks. Table 2 shows the different species incriminated in the transmission of RVFV during the 




Figure 3: Map showing RVF endemic countries, and countries at risk.  (Source: [29]) 
 
Table 2: Mosquito species incriminated in the transmission of RVFV during the outbreaks recorded in East 
Africa and the Middle East (Source:  [19]) 
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RVF virus can be transmitted in utero to the foetus of ruminants, camels and other species. This virus may also 
infect other animals exposed to abortion or birth products, which contain large amounts of virus; however, the 
importance of this route is controversial.   
Virus shedding in secretions and excretions from infected ruminants is not important in spreading Rift Valley 
fever. 
Humans can acquire RVF virus by direct contact with infected tissues, contact with aerosolized viruses generated 
in laboratories or during slaughter, or from mosquitoes. The relative importance of mosquito-borne exposure 
and exposure to infected animal tissues continues to be debated. Drinking raw (unpasteurized) milk is a 
significant risk factor for human infection, although definitive proof for this route is lacking. Vertical transmission 
to human infants has been demonstrated in at least 2 cases. Person-to-person (horizontal) transmission does 
not seem to occur, but the blood and tissues of patients might be sources of exposure for medical personnel. 
 
Epidemic RVF disease patterns 
A number of factors play a role in the occurrence of outbreaks:  
(i) the presence and circulation of the RVF virus by mosquito vectors;  
(ii) the mosquito pressure (number of breeding sites and hatching frequency), which is highly dependent on 
environmental conditions, particularly rainfall events; and  
(iii) the distribution of domestic animal hosts, essentially ruminants (goats, sheep and cattle), vulnerable to 
increased vector/host contacts at night. However, there is extensive species susceptibility to RVF, as set 
out in Table 1. 
In endemic countries, RVF tends to reoccur at varying interval periods that can last several years. The patterns of 
outbreak in certain countries, such as Kenya, have been studied and used to develop risk maps, which are useful 
for control strategies. (Figure. 5; [37]) 
Ideal conditions for emergence of RVFV-infected mosquitoes occur after flooding when unusually heavy rains 
affect the country. The Aedes spp. floodwater mosquito is the primary vector: it transmits the virus trans-
ovarially and when surface water accumulates the infected mosquito eggs which were dormant, can hatch and 
give birth to infected mosquitoes which feed on livestock or humans and transmit the virus. Infected ruminants 
develop a high viremia providing a source for secondary vectors such as Culex spp. mosquitoes to be infected 
and further spread the virus by biting other animals and humans. During epidemics (Figure 4), the virus can also 
be transmitted directly from infected to healthy ruminants. Transmission to humans through contact of infected 
animal tissues and blood appears to be a common mean of infection [15]. This is attested by the number of 
human cases among butchers, veterinarians and shepherds who contaminate themselves via abrasions of the 
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skin, or through mucosal membranes of the respiratory tract. For this reason, it is highly recommended to 
veterinarians to wear gloves, gowns and face masks. As stated earlier, the suggestion that humans can become 




Figure 4: Epidemiology of RVF: Endemic and epidemic cycles. Source: EFSA RVF risk assessment report, 2005 
 
The mechanisms that maintain RVF virus in nature and cause it to emerge in epidemic form are incompletely 
understood, and might differ between areas. It is believed that there is a transovarial transmission in 
mosquitoes: mosquito eggs remain dormant in soil for long periods of time, surviving long dry spells. There may 
be low level circulation of the virus. These eggs would hatch in big numbers during heavy rainfall.  
Transmission cycles are best understood in savannah regions, where the virus is thought to survive between 
outbreaks in the dried eggs of Aedes mosquitoes found in shallow depressions in the soil (dambos). Infected 
mosquitoes are thought to hatch when the dambos fill after heavy rainfall, and initiate transmission cycles 
involving additional mosquito species, and animals that act as amplifying hosts. The vertebrate amplifying hosts 
are thought to be critical in propagating epidemics. Virus transmission has also been demonstrated at low levels 
in livestock, wildlife and humans during interepidemic periods. Infection cycles in some other climates, such as 
forested regions, are poorly understood and might differ from this pattern. 
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Table 3 below summarises the major clinical signs observed in ruminant livestock. 
In endemic regions, epidemics of RVF are characterized by high mortality rates in new born animals and 
abortions in adults. Between epidemics, this virus can circulate without apparent clinical signs in susceptible 
species, or there may be sporadic abortions that could be confused with other diseases. 
Clinical signs depend on the species of animal affected and conditions such as age and pregnancy. During 
epidemics the occurrence of numerous abortions and mortalities among young animals, together with disease in 
humans, is characteristic. Pregnant sheep and cattle affected by this disease will almost always abort (80-100%). 
Young lambs and calves develop a fever, become weak and die very suddenly. The mortality rate in young 
animals is very high whereas mortality in adult sheep is about 20 per cent and about 10 per cent in adult cattle. 
Adult sheep and cattle may have nasal discharge, excess salivation, and loss of appetite, weakness, or diarrhoea.  
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In lambs where RVF is usually most severe, nonspecific signs of fever, anorexia, weakness and lymphadenopathy 
are common. Haemorrhagic or fetid diarrhoea, melena, regurgitation, signs of abdominal pain, a 
serosanguineous or bloodstained mucopurulent nasal discharge and elevated respiratory rate may also be seen. 
Very young lambs and kids with clinical signs rarely survive longer than a few days, and often die with 24 hours.  
Older animals may die acutely or peracutely, recover from the illness, or become infected with few or no clinical 
signs. Similar signs have been reported in young calves, although some sources have reported that icterus is 
more likely, and survival rates appear to be higher. 
Abortions, apparently unrelated to the gestation period, are the most characteristic signs in adult sheep, goats 
and cattle. There are also reports of abortions in wild ruminants including African buffalo, a waterbuck (Kobus 
ellipsiprymnus), a springbuck (most likely Antidorcas marsupialis) and a blesbuck (probably Damaliscus dorcas). 
Some pregnant animals have few or no clinical signs other than abortion, while others become ill or die. 
 
Table 3: Summary of the RVFV clinical signs in livestock 
 
Cattle Sheep 
Calves (highly susceptible) Newborn labs or under 2 weeks of age (extremely 
susceptible) 
• Fever (40-41°C) 
• Inappetence 
• Weakness and depression 
• Bloody or fetid diarrhoea 
• More icterus than in lambs 
 
• Biphasic fever (40-42°C); subsides just prior to death 
• Anorexia, in part due to disinclination to move 
• Weakness, listless 
• Abdominal pain 
• Rapid, abdominal respiration prior to death 
• Death within 24-36 hours 
 
Adults (moderately susceptible) Lambs over 2 weeks of age (highly susceptible) and adult 
sheep (SAME FOR GOAT) 
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• Often inapparent infection but some acute 
disease 
• Fever lasting 24-96 hours 
• Dry and/or dull coat 




• Bloody/fetid diarrhoea 
• Fall in milk yield 
• Abortion rate may reach 85% in the heard 
• Peracute disease: sudden death with no appreciable 
signs. 
• Acute disease more often in adult sheep. 
• Fever (40-42°C) lasting 24-96 hours 
• Anorexia 
• Weakness, listlessness and depression 
• Increased respiratory rate 
• Vomiting 
• Bloody/fetid diarrhoea 
• Mucopurulent nasal discharge 
• Icterus may be evident in a few animals 





Suspicion of RVF could generally be made when heavy rains are followed by the occurrence of abortions in 
sheep, cattle and goats together with fatal disease, particularly in young and pregnant animals, which is marked 
by necrotic hepatitis and widespread haemorrhages. Frequently there is also influenza-like illness in farm 
workers. 
Specimens to be submitted for laboratory confirmation of the diagnosis include heparinized or clotted blood, 
plasma or serum of live affected animals or tissue samples, including liver, spleen, kidney, lymph nodes and 
heart blood of dead animals. Samples from aborted foetuses should include brain since this is usually less 
autolysed or putrefied than viscera. 
The OIE recognized tests are as follows: 
• Identification of the agent:  
o Isolation in cell culture 
o Isolation in suckling mice 
o Reverse transcription PCR (agarose based and real time) 
o Antigen detection by antigen ELISA 
o Histopathology 
• Serology: 
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o IgM ELISA: (for recent infection) 
o Indirect IgG ELISA 
o Virus neutralisation (the prescribed test for international trade) 
Table 4 shows the tests recommended by the OIE for the different purposes: to demonstrate population or 
individual freedom, confirmation of clinical cases, etc.  
 




Key: +++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or 
other factors severely limits its application; - = not appropriate for this purpose.  
Although not all of the tests listed as category +++ or ++ have undergone formal validation, their routine nature and the 
fact that they have been used widely without dubious results, makes them acceptable.  
RT-PCR = reverse-transcription polymerase chain reaction; ELISA = enzyme-linked; immunosorbent assay; VN = Virus 
neutralisation.  
 
Indirect IgG ELISA’s are the tests most commonly used in low & middle income countries, even though in limited 
manner. The commercially available tests are generally expensive therefore limiting their use in most control 
programs 
IgG RVF ELISA include whole virus antigen and those based on the nucleoprotein 
Due to the lack of DIVA vaccine to date, there is no DIVA diagnostic assay available, although the current ELISA 















Prevale ce of 
infection-
surveillance




Virus isolation in cell 
culture - - - +++ + -
Virus isolation in 
suckling mice - - - + + -
RT-PCR - - - +++ + -




- - - ++ - -
ELISA +++ ++ +++ ++ +++ +++
Virus Neutralisation +++ +++ +++ ++ ++ +++
Agent identifictaion (3)
Detection of Immune response (4)
Purpose
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Humans can acquire RVF virus by direct contact with infected tissues, contact with aerosolized viruses generated 
in laboratories or during slaughter, or from mosquitoes. The relative importance of mosquito-borne exposure 
and exposure to infected animal tissues continues to be debated. Drinking raw (unpasteurized) milk is a 
significant risk factor for human infection, although definitive proof for this route is lacking. Vertical transmission 
to human infants has been demonstrated in at least 2 cases. Person-to-person (horizontal) transmission does 
not seem to occur, but the blood and tissues of patients might be sources of exposure for medical personnel. 
In humans, people with RVF will either show no symptoms or develop a mild illness. Signs of illness include 
fever, weakness, myalgia (muscle pain), back ache, dizziness, liver abnormalities, and weight loss. In some 
patients, the illness can progress to haemorrhagic fever, encephalitis (inflammation of the brain), or ocular 
disease (inflammation of the eye, blindness). Severe complications develop in 1-4% of cases though most people 
recover within four to seven days. Approximately one per cent (1%) of humans infected with Rift Valley fever 
dies of the disease. 
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Incidence and Prevalence in Selected Countries 
Global  
RVF has up to now been restricted to the African continent and the Middle East, both in enzootic and epizootic 
(and epidemic) ways, with the epizootic and epidemic forms being generally what is widely publicised and 
reported.  Figure 6 and Table 5 show the countries where the disease is endemic and those where epizootics 
have been reported. In the last decade RVF has been reported in Somalia (2006–2007), Kenya (2006–2007), 
Tanzania (2007), Sudan (2007–2008), Comoros (2008), Madagascar (2008–2009), South Africa (2008, 2009, and 




Figure 6: Distribution of RVF as of 2011.  Countries that have experienced substantial epizootics and 
epidemics are shown in dark blue, while those with serological evidence or virus isolation are marked with 
light blue. (Source: [51]) 
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Year Place Reported deaths in 
1930 Kenya sheep 
1950-51 Kenya sheep 
1975 South Africa sheep cattle, humans 
1977 Egypt humans 
1987 Mauritania, Senegal humans, sheep 
1991,96-97 Egypt humans, sheep 
1997-98 Kenya, Somalia, Tanzania humans, sheep 
1998-99 Mauritania, Senegal humans, sheep 
2000-2001 Saudi Arabia, Yemen humans, sheep 
2007-2008 Sudan humans, sheep 
2008-10 South Africa humans, sheep, cattle 
2010 Mauritania humans, sheep, cattle 
2010 South Africa humans, sheep 
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Incidence data by country 
The number of outbreaks reported can be obtained from the OIE and from AU-IBAR. The information is not always 
similar, as many countries do not seem to report, or to do it in a routinely manner.  
 
1- OIE:  The number of outbreaks reported to the OIE in the countries of interest, can be seen in Table 6 below.  
Note that the disease is not present in the Asian countries of interest. 
 
Table 6: Number of RVF outbreaks reported to the OIE between 2005-2015 (Numbers given only for the 
target countries) Source: OIE.  
http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
West Africa 
Burkina Faso - - - - - - - - - - - 
Ivory Coast - - - - - - - - - - - 
Mali 0 0 0 0 0 0 0 0 0 0 - 
Senegal 0 0 0 0 0 0 0 +? 4 1 1 
East Africa 
Ethiopia 0 + 0 0 0 0 0 0 0 0 - 
Kenya 0 21 15 0 0 0 0 0 0 0 0 
Rwanda - 0 0 0 0 0 0 4 26 - - 
Tanzania 0 ? 19 0 0 0 +? 0 0 0 0 
Uganda 0 0 0 0 0 0 0 0 0 0 - 
Southern Africa 
Madagascar +? +? +? 18 1+ 0 0 0 0 0 - 
Malawi +? +? +? +? +? +? +? +? ? - - 
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Mozambique 0 0 4 +? 0 0 0 0 6 4 - 
South Africa 0 0 0 31 40 492 134 0 0 0 - 




2- AU-IBAR:  The number of outbreaks reported to AU-IBAR is included in the Pan African Animal Resources Year 
Book. (http://www.au-ibar.org/pan-african-animal-resources-yearbook?showall=&limitstart=) and can be 
seen for the countries of interest in Table 7 below.   
Table 7: Number of RVF outbreaks reported to the AU-IBAR from 2005 to 2015 (numbers given only for the 
target countries). Source: AU-IBAR Year Books. 
 
Country 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
West Africa 
Burkina Faso - - - - - - - - - -  
Ivory Coast - - - - - - - - - -  
Mali - - - - - - - - - -  
Senegal - - - - - - - - 10 1  
East Africa 
Ethiopia - - - - - - - - - -  
Kenya - - + - - - - 1 1 2  
Rwanda - - - - - - - - - -  
Tanzania - - + - - - - - - -  
Uganda - - - - - - - - - -  
Southern Africa 
Madagascar - - - 1 - - - - - -  
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Malawi - - - - - - - - - -  
Mozambique - - - - - - - - - -  
South Africa - - - 34 41 330 74 - - -  




There is a very good and recent systematic review of the Rift Valley fever epidemiology from 1931-2014 by 
Nanyingi et al. [38]. In this publication, the gradual spread and geographical extend of the disease is presented.  




Figure 7: Map of Africa and the Arabian Peninsula illustrating the spatial and temporal distribution of Rift Valley fever 
cumulative outbreaks in days from 1997-2012.  Source: [38]) 
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Incidence data by country 
The information below has been obtained from PubMed and internet engine search.  The information by 
country is limited, as it tends to focus on the outbreaks, and not in the inter-epidemic periods.  
 
Table 8: Prevalence of RVF in the different countries (Data from 2000-2015) 
 
Country Year Area Species N samples 
tested 
% Positive Reference(s) 













 2013 Northern Camels 270 SNT: 51.85 5 
Côte d'Ivoire       No recent 
publications 
Ethiopia      No recent 
publications 
Kenya 2015 Northeast Humans 1082 15 26 
 2007 From AIDS 
indicator survey 
Humans 1091 4.5 42 
Madagascar 2009 Highlands Cattle 2009: 894 
2010: 
Anorana 7 
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Small ruminants: 24.7 
Malawi      No publications 
found 






Cattle 404 36.9 29 
Rwanda      No publications 
found 
Senegal 2012 Case contacts of 










Only 3 tested 
positive.  Assumed 
infected for being in 




 2007 211 locations  16738  9 
 2004 Ferlo region Small 
ruminants 
260 2.6 8 













Buffaloes 227 Crocodile Bridge: 36.3 






Buffaloes 1615 (82 
herds) 
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 2011? Kigoma region Small 
ruminants 







 2010 Northern 
Tanzania 
Camels 109 Individual: 27.5 




Mbeya Humans 1228 Overall: 5.2 
Close to lake Malawi: 
29.3 (N:150) 
18 
Uganda      No recent 
publications 
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Economic and Social Impacts at Global 







Enzootic and epizootic RVF have generally significant socio-economic impact in affected areas, essentially due to 
the zoonotic nature of the disease and morbidity and mortality in livestock.  
The serious impact of RVF epidemics and epizootic is generally associated to a number of factors including: 
o Morbidity and mortality in livestock 
o Disruption into the meat industry resulting from the ban in livestock slaughter;  
o Disruption to livestock markets  
o Subsequent disruption to the livelihood of all actors in the livestock value chain 
o Disruption to the country’s economy, including tourism  
As a matter of fact, RVF impacts heavily on pastoralists who keep and trade small and large ruminant. In the 
horn of Africa Export of livestock income, most of which come from pastoralists, can represent up to $300 
million USD [20][6] 
Socio-economic impact of RVF epizootics is well summarised in the Figure 8 below. Sadly, socio-economic impact 
studies have been so far conducted only on a limited number of countries, mainly in East African and the Horn of 
Africa regions (Kenya, Tanzania, Sudan, Somalia etc.) and in South Africa. 
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Figure 8: Socio-economic impacts of RVF per sector, level and type of effects induced.  The links between 
the disease and the different sectors and level impacted (health related costs) are represented by straight 
(red) arrows; the links between the different sectors and level impacted (non-health related costs) are 
represented by the bent (blue) arrows.  (Source: [43]) 
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Table 9: Overview of the different types of socio-economic impact induced by Rift Valley fever, their broad characteristics and their estimation 








Type of Effect (code) 
(timescaleb) 
 
Financial estimate per country (Reference) 
Producers (1) Microeconomic 
Household 
economy 
Food security and 
livelihood 
economy 
Livestock losses (1.1) 
(short term) 
Kenya: $9.3 million USD (Lichoti, 2009; Rich et al., 
2009; Rich and Wanyoike, 2010; Sindato et al., 
2012) 
 
Somalia: $47–55 million USD (Ahrens, 1998; 
Soumar'e et al., 2006) 
Yemen: $0.6 million USD (Handlos, 2009) 
Saudi Arabia: no estimates 
Losses in production 
(1.2) (short term) 
Kenya, Milk ($2 million USD) (Lichoti, 2009) 
Somalia, Yemen, Saudi Arabia: no estimates 
Abortion; destocking; redistribution 
effects (inequalities) (1.3) (long term) 
No estimates 




Livestock losses (2.1) Kenya ($32 million USD) (Rich et al., 2009; Rich and 
Wanyoike, 2010; Orinde et al., 2012) 
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(short term) Yemen ($15 million USD) (Handlos, 2009) 
Saudi Arabia ($5.3 million USD) (Mohammed, 
2007) 
Somalia, no estimates 
Trading bans impact on local value chain 
(local market losses) (2.2) (short term) 
Kenya ($10 million USD) (Rich and Wanyoike, 2010; 
Orinde et al., 2012 
Somalia ($29–45 million USD) (Ahrens, 1998; 
Holleman, 2002; Nin Pratt et al, 2005; Cagnolati et 
al., 2006; Soumar'e et al., 2006)  
Yemen, Saudi Arabia: no estimates 
 
Value chain restructuration, consumer 







National economy Transport; tourism; trading bans (3)  
(short and long term) 
Yemen, tourism ($30 million USD) (Handlos, 2009) 
Kenya, Somalia, Saudi Arabia: no estimates 
International Trade 
(4) 
Macroeconomic National economy Trading bans impact on import/export; 
public treasury and exchange rate losses (4) 
(short and long term) 
Kenya ($ 10 million USD) (USAID, 2008; Rich and 
Wanyoike, 2010; Orinde et al., 2012; 44) 
   Somalia ($330 million USD) (Ahrens, 
1998; Holleman, 2002; Nin Pratt et al., 
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2005; Soumar'e et al., 2006) 
Yemen ($50 million USD) (Handlos, 2009)  
Saudi Arabia: no estimates 







Human death (5.1)  
Private treatment (5.2) (short and long term) 
Kenya 1% of total DALY (household costs: $82 000 
USD) (Orinde et al., 2012)  
Yemen ($12 million USD, human death) (Handlos, 
2009) 
Prevention and control 
(human infections) (5.3)  
(short and long term) 
Somalia and Saudi Arabia: no estimates 








Private surveillance and control in livestock 
(6.1) (Short and long term) 
 
Public surveillance and control in livestock 
(6.2) 
(short and long term) 
Kenya ($2.5 million USD, short term) (Lichoti, 
2009; Rich & Wanyoike, 2010) 
Yemen ($ 0.1 million USD, vector control) 
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Table 10: Number of RVF outbreaks reported to the AU-IBAR from 2005 to 2015 (numbers given only for the 






Human  Animal  Estimated economic 
impact 
Cases Deaths  Cases Deaths  US$ (x106) % GDP 
(PPP) 
1950–1951 South Africa nd nd  600 000 100 000  nd nd 
1977–1978 Egypt 200 000 594  nd nd  115 0.8 
          
1978 Zimbabwe nd Nd  70 000 10 000  nd nd 
1997–1998 East Africaa 89 000 478  ndb Nd  >250 ndc 
2000–2001 Saudi Arabia 883 123  >10 000 1000  10 0.02 
          
2000–2001 Yemen 1328 166  22 000 6000  107 0.8 
2006–2007 Kenya 684 155  >4400 235  66 0.1 
          
2006–2007 Somalia 114 51  nd Nd  471 5.5 
2006–2007 Tanzania 264 109  32 000 4200  6,7 0.01 
2008–2009 Madagascar >650 21  23 18  nd nd 
2008 Sudan 698 222  nd Nd  nd nd 
2010–2011 South Africa 186 18  >15 000 9000  nd nd 
This list is a non-exhaustive list, and complete information on RVF outbreaks could be found on World Animal Health 
Information database (WAHID) at http://www.oie.int/wahis/public.php  $USD, United States Dollar; GDP (PPP), gross 
domestic product at purchasing power parity; nd, not determined. aKenya, Somalia and Tanzania, bOnly available for 
Kenya: 70% of sheep population, 20–30% of camel and cattle, cAvailable for Somalia: US$186 million, 4.3%GDP (PPP). 
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Theoretically tools that could be used for the control and prevention of RVF epizootics include vector control, 
surveillance and early warning systems, better herd immunity and treatment.  
 
Early detection  
Given the long and inconsistent inter-epidemic period in RVF enzootic regions and the devastating nature of 
outbreaks, it has become critical to put in place early detection and warning systems and mechanisms, especially 
in endemic and high-risk regions. 
For early detection of the disease, a commonly used practice in Africa has been the use of Sentinel Animals.  
Sentinel herd monitoring has been used in different parts of Africa to monitor viral circulation in susceptible 
populations. It can be enhanced by the additional monitoring of climatic parameters. 
o Sentinel animals are usually located or established in geographically representative areas, and in 
zones where mosquito breeding activity is likely to be greatest, e.g. near rivers, swamps and dams. 
o In order to be effective and more reliable, sentinel herds should be monitored in conjunction with 
the monitoring of other risk indicators such as climatic parameters.  
o Generally 30 naïve young female sheep or goats, 12 to 15 months old are selected after the owners 
have been sensitised and incentivised (such as free deworming etc.). It is recommended that not less 
than 20 animals are kept at each location  
o They are screened for freedom of IgG and IgM in order to be included in the sentinel program. They 
should then be monitored regularly. 
Unfortunately, many established sentinel herds in several African countries (Senegal, Mauritania, Kenya) are not 
regularly screened due to the high cost of commercial diagnostic tests (ELISA) and the cost involved in their 
regular monitoring, as they tend to be in areas remotely located from laboratories.   
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Early warning and satellite imagery 
Each of the documented moderate or large RVF outbreaks that have occurred in the Horn of Africa over the last 
60 years have been associated with El Niño/Southern Oscillation (ENSO) phenomena above normal and 
widespread rainfall, except for few localised cases [2].  
Retrospective analysis of a satellite-derived time series vegetation measurements of photosynthetic activity, 
known as the normalized difference vegetation index [2], has shown that such data, in combination with other 
climate variables, can be used to map areas where RVF occurred. 
Based on the above, satellite and other data have been allowing in recent years the FAO, through its Emergency 
Prevention System for Transboundary Animal and Plant Pests and Diseases (EMPRES)/Livestock Programme, to 









The viability of mosquito eggs in dambo soil can be reduced by burning of the grass cover, and strategically-
timed application of larvicides can be used to suppress mosquito breeding. 
Other measures, such as chemical control of adult vectors, movement of stock from low-lying areas to well-
drained and wind-swept pastures at higher altitudes, or confining of animals to mosquito-proof stables, are 
usually impractical, instituted too late and at best palliative in the face of a RVF epidemic. 
 
Immunization 
Immunization remains the only effective method of protecting livestock. It is however practices differently in 
different endemic countries (Table 11):  
• Countries practicing or recommending preventive yearly vaccination, even during inter-epidemic period: 
South Africa and other Southern African countries (Namibia, Botswana), Saudi Arabia, Egypt 
• Countries vaccinating on first indications of outbreaks: Kenya, Tanzania, Sudan 
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• Countries not practicing vaccination even during epidemics: Mauritania, Madagascar, Senegal 
 
Until the recent registration of RVF Clone 13 in South Africa in 2009, the only available RVF vaccines were the 
live attenuated Smithburn, produced by OBP and KEVEVAPI in South Africa and Kenya respectively, and the 
inactivated vaccine produced in limited quantities by OBP and the Egyptian Vaccine and serum institute. The 
poor safety of the Smithburn, especially in pregnant animals and the need for a booster dose after primo-
vaccination for the inactivated RVF had prevented many countries in Africa, especially in West Africa, to institute 
vaccination. This has resulted in lack of effective control during outbreaks or in inter-epidemic periods.  
The RVF Clone 13 although safer than the Smithburn vaccine and requiring single vaccination (advantage over 
the inactivated vaccine) is still not widely available and currently has been discontinued by OBP due to stability 
problems.  
 
Table 11: Control strategies for RVF depending on its epidemiological situation 
 
RVF Situation Examples of countries Current control strategy 
Endemic with regular outbreaks Kenya, Tanzania, Egypt, Senegal, 
Mauritania 
• Vaccination at first sign of an outbreak: 
Kenya, Tanzania. 
• Continuous vaccination: Egypt 
• No vaccination: Mauritania, Senegal 
Endemic with sporadic / re-
occurring outbreaks 
South Africa, Saudi Arabia Continuously / yearly vaccination 
Free – High risk Middle East, North Africa (Active) surveillance 




Disease situation and government policies by country  
Tables 12 and 13 will be updated and completed once the results from the questionnaires sent to the DVS 
offices of the different countries are received.  
The first table covers the disease situation (if it is notifiable or not), the presence of official surveillance and/or 
control programs, and the treatment situation.  The second table refers to vaccination. 
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The definitions that were given to the respondents are: 
1Surveillance: is the systematic ongoing collection, collation and analysis of data and the timely dissemination 
of information to those who need to know so that action can be taken.  
2Control: a programme which is approved, and managed or supervised by the Veterinary Authority of a country 
for the purpose of controlling a vector, pathogen or disease by specific measures applied throughout that 
country, or within a zone or compartment of that country 





















Burkina Faso      
Côte d'Ivoire (Ivory 
Coast) 
Yes - No - - 
Ethiopia      
Kenya Yes Yes, active & 
passive 
YEs No No 
Madagascar      
Malawi Yes Yes, passive No N/A N/A 
Mali Yes Yes, passive N/A N/A N/A 
Mozambique      
Rwanda Yes Yes, active & 
passive 
Yes Yes No 
Senegal      
South Africa      
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Tanzania Yes Yes, active & 
passive 
Yes No No 
Uganda Yes No No N/A N/A 
Zambia Yes Yes, passive Yes N/A N/A 
 
-: Questionnaire left blank by respondent 
















Species vaccinated (cattle, 
sheep, goats, pigs, poultry) 
Burkina Faso     
Côte d'Ivoire (Ivory 
Coast) 
No - - - 
Ethiopia     
Kenya As per control 
program 
Combination Both Cattle, sheep and goats 
Madagascar     
Malawi No N/A N/A N/A 
Mali N/A N/A N/A N/A 
Mozambique     
Rwanda Yes Government Official Cattle, goats and sheep 
Senegal     
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Additional vaccine and vaccination strategies for RVF control 
One of the biggest challenges to the control of RVF through the use of vaccines remains the design of suitable 
vaccination strategies. The cyclical nature of the disease and the subsequent long inter-epidemic periods have 
resulted in many countries considering the use of vaccination only at first indication of an outbreak. 
Control strategies that promote the establishment of good herd immunity in the livestock population in endemic 
regions are more likely to reduce the devastating impact of severe outbreaks. As discussed earlier, a number of 
factors prevent many endemic countries from putting into place effective control strategies for RVF. Key 
obstacles to effective RVF control include: 
• The cyclical nature of RVF and long inter-epidemic period; 
• The specific policies on the control of RVF or lack of emergency preparedness strategy for RVF outbreaks 
in many countries; 
• Poor diagnostic capacity when the diagnostic laboratory is located far from high risk areas where the 
disease tends to start, while limited resources prevent the conduct of RVF activities outside outbreak 
seasons (high cost of diagnostic tests, logistical challenges in regular transport of samples from sentinel 
animals etc.); and 
• The high pressure on the few RVF vaccine manufacturers, because of their limited production 
capabilities, when there are outbreaks in more than one country. 
In order to address these two initiatives have been explored: the use of combination vaccinations and vaccine 
banks or strategic reserves. 
1- Combination vaccines including RVF and a vaccine for a disease widely and regularly use, such as Sheep & 
goat pox for small ruminants, and Lumpyskin for cattle have been explored for a number of years now. The idea 
is that such vaccines would rely on the regular vaccination of animals for Lumpyskin disease in cattle and sheep 
and goat pox in sheep and goat respectively, in order to build immunity in vaccinated animals to RVF. Pox 
South Africa     
Tanzania  Yes Government, Private, 
NGO 
Both Cattle, sheep, goats 
Uganda No Never vaccinated N/A N/A 
Zambia No N/A N/A N/A 
 
-: Questionnaire left blank by respondent 
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recombinant vaccines with Lumpyskin or sheep/goat pox as vector have been tried by different groups with little 
progress toward a commercial vaccine to date. A combination vaccine including RVF Clone 13 and Lumpyskin 
Neethling strain was evaluated by OBP, but with limited progress to date due to the poor stability of the OBP 
Clone 13 vaccine. 
2- A RVF vaccine/vaccine antigen bank for a monovalent RVF vaccine: the concept is to use strategic stocks of 
vaccine managed by the manufacturer for a region, or vaccine antigens stocked taking into account the need for 
emergency production.   
Vaccine banks or strategic stocks are suitable for Regional strategies for the control of RVF, and are expected to 
encourage more cohesive policies and mutual support between different countries. A number of initiatives were 
initiated in the Southern Africa Development Community (SADC) region. These initiatives included the 
evaluation of RVF risk in each country through the development of risk maps based on historic data on the 
occurrence of the disease, a RVF policy landscaping in order to understand current policies setup in each country 
around RVF control, and the establishment of a technical RVF [11] 
An additional tool that is required for a more effective RVF vaccination strategy is a RVF field test in the form of 
lateral flow device or pen-side test, which allows for testing animals in situ, avoiding costly shipment of serum 
specimens to laboratories. 
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There are different types of vaccines for RVF. Table 14 shows a summary of the characteristics of the main 
vaccines and its commercial status. 
Table 14: Vaccination for RVF in the countries of interest  
 
Vaccine Strain Status 
Inactivated  
(OBP, VSVRI) 
Pathogenic field strain Commercially available since 1970s in SA. 
Essentially used in cattle.  
Live attenuated 
(OBP, KEVEVAPI) 
Smithburn Commercially available 
Avirulent natural mutant Clone 13: natural deletion in 
S segment 
Registered in SA. 
Production suspended due to stability challenges 
 
 
Commercial vaccines manufactured in Africa and Asia  
 
The information summarised in Table 15 is based on information from The Center for Food Security and Public 
health, Iowa State University (www.cfsph.iastate.edu/vaccines/index.php and Vetvac (www.vetvac.org).   
More details have not been gathered, as it has been assigned to another consultant.  
To date registered commercial RVF vaccines are only produced in South Africa, Kenya and Egypt. MCI in Morocco 
has also registered a RVF Clone 13 vaccine which has not yet been used in another country. African countries 
other than the above three that have used the RVF vaccine are Namibia, Botswana, Tanzania, and Sudan. They 
have generally imported the RVF vaccine from OBP in South Africa and to a limited extent from KEVEVAPI.    
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Table 15: RVF vaccines manufactured in Africa 
 
Manufacturer Country Name & Strain Vaccine Type Countries distribution 
Onderstepoort Biological 
Products 
South Africa Smithburn Live South Africa, Namibia 
RVF inactivated vaccine Killed South Africa 
RVF Clone 13 Live South Africa 
Veterinary Serum and Vaccine 
Research Institute 
Egypt Smithburn Live Egypt 
RVF inactivated vaccine 
Zagazig H501 
Killed Egypt, Arab Rep. 
KEVEVAPI Kenya Riftvax 
Smithburn 
Live Kenya 
MCI Santé Animale Morocco Clone 13T Live Morocco 
 
 
Commercial vaccines imported into Africa 
 
The information summarised in Table 16, is based on a questionnaire send to the Director of Veterinary Services 
office and regulators of the countries of interest.  Note that some vaccines might have been imported under DVS 
dispensation, and they are not necessary licensed in the country.  
 

























Burkina Faso N/V**       
Côte d'Ivoire 
(Ivory Coast) 
N/V       
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Ethiopia N/V       
Kenya - - - - - - - 
Madagascar        
Malawi      N/A N/A N/A N/A N/A N/A N/A 
Mali N/V       
Mozambique        
Rwanda Riftvax  Kenya 55,000 40,000 25,000 5,000 
Senegal N/V       
South Africa        
Tanzania  Smithburn  South Africa    400,000 






 Smithburn South Africa   1,500  
 Clone 13 South Africa   2,000  
 Live 
attenuated 
South Africa  23,300 10,000  
 N/A South Africa 11,000  35,600  
 Inactivated South Africa 75,000    
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Preventing and controlling RVF through vaccination will be based on different key principles whether it is for an 
endemic region or for a region at risk of new introduction. In other word, while there are generic characteristics 
that the vaccine should have, some will be specific to endemic regions and other for regions free of the disease, 
and at risk.   
As is the case for many diseases endemic in certain areas and posing a risk to free countries, the key 
characteristics of the ideal vaccine may vary. Below are some attributes that will be needed for vaccines 
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Some of the major characteristics to be considered for the ideal RVF vaccine were summarised at GF-TADs 
meeting organised by the FAO in January 2011: 
Safety 
No reversion to virulence; 
Lack of abortion in vaccinated animals; and 
Non-teratogenic 
Efficacy 
Prevention of viremia; 
Rapid onset of immunity; 
Long-lasting immunity; 
Prevention of abortion on challenge; 
Prevention of clinical disease; 
Produce immunity in young animals; 
Target key susceptible ruminant species; and 
Single-dose regimen 
 
The Target Product Profiles (TPPs) reflect the availability and utility of current agents and incorporate features 
that will be necessary to improve on the current products and to address unmet needs, taking into account the 
particular requirements of the poorest livestock keepers.   
The TPPs are more robust when they include the opinions and consider the needs of the different stakeholders.  
While efforts have been made to encompass them, the TPP in Table 17 below should be considered a proposal, 
a live document subject to improvements.  
Table 17: Target Product Profile (TPP) RVF vaccine  
 
 Attribute Minimum (current available vaccine) Ideal 
1 Antigen 
 
Immunogen with protective antigens of 
RVFV 
Immunogen with protective 
antigen of RVFV 
2 Indication for use For active immunization of sheep, goats 
& cattle  
For active immunization of sheep, 
goats, cattle and camels  
3 Recommended species Cattle, Sheep and goats All RVF susceptible livestock  
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4 Recommended dose 2 ml 1 ml 




vaccine) or ready to use solution 
(inactivated vaccine) 
Ready to use solution/suspension 
6 Route of administration SC  SC, Intramuscular or pour on 
7 Regimen - primary 
vaccination 
Single dose Single lifetime dose 
8 Regimen - booster Single annual booster Lifelong immunity after primary 
vaccination 
9 Epidemiological releance Protection against RVF  Protection against RVF and 
prevention of virus transmission 
10 Recommended age at first 
vaccination 
• Animals over 6 months: one 
injection 
• Animals under 6 months: two 
injections at a 2 to 6 month interval; 
the second injection should only be 
given to animals over 6 months old. 
From 1-2 months of age  
11 Onset of immunity 
 
2-3 weeks following primary vaccination One week following primary 
vaccination 
12 Duration of immunity At least 1 year Lifelong immunity 
13 Expected efficacy To prevent disease & prevent mortality. To prevent infection and 
transmission. No disease & no 
mortality in vaccinated animals 
after virulent challenge. 
14 Expected safety In animals under 6 months of age, a 
transient pyrexia reaction can occur.  
A transient nodular reaction of varying 
importance, may appear at 
the injection site, it progressively 
disappears within 1 to 2 months.  Only 
No post-vaccinal reactions at any 
age. Safe for pregnant animals.  
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vaccinate pregnant animals on 
emergency. 
15 Withdrawal period Nil Nil 
16 Special requirements for 
animals 
Do not vaccinate un-healthy animals Do not vaccinate un-healthy 
animals 
DIVA 
17 Special requirements for 
persons 
 None None 
18 Package size 50 doses Multiple pack size from 20 doses 
19 Price to end user 
 
Not more than $0.50/dose $0.20/dose at end user  
20 Storage condition and shelf-
life as packaged for sale 
12 months at 4-8° C   
 
 24 months 4-8° C and/or 48 hours 
at 30° C 




Overall conclusion for improved RVF control through vaccination 
Some important point for consideration, that would lead to the ideal vaccine are discussed below 
Need for validated challenge models not posing a risk to the researchers:  
The most suitable way to evaluate a RVF vaccine is through challenge studies, involving a virulent RVFV strain. 
There are also a limited number of virulent RVFV strains around, that are capable of consistently reproducing 
the disease. In vitro models could be considered but most of them are not properly validated. There is therefore 
a need for reliable fully validated challenge models in target animals; while also validated correlate for 
protective immunity for in vitro efficacy models.   
Promote the development of multivalent vaccines including RVF: 
This will indirectly improve the uptake of RVF vaccine through continuous vaccination, thus improve herd 
immunity to RVF. Likely combination include LSD-RVF; using a LSD strain that is also protective against sheep and 
goat pox would make such vaccine suitable for both cattle, sheep and goat, all over affected regions of Africa. 
Another combination is RVF with CBPP, for use in cattle in East and Western Africa. 
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Promote RVF vaccine bank (stockpile or strategic reserves) at regional levels 
Considering the fact that RVF epidemics generally affect several countries simultaneously, putting a strain on 
vaccine production capacity, preparedness strategies should include strategic reserves or antigen, half product 
or ready to use vaccines. The size of the reserve should be determined on the basis of risk mapping studies in 
affected countries.   
Additional considerations indirectly connected to the above are: 
• The need for an effective human vaccine (to protect livestock keepers, but also research and animal health 
personnel)  
• The need for field diagnostic assay 
• Development of risk maps in all endemic countries, similar to those already produced for Kenya and South 
Africa 
The present review has discussed a large number of candidate RVF vaccines developed to date, and having 
reached different stages of development. There is still no candidate that has demonstrated DIVA characteristics, 
although theoretically this seems to be possible with some of them. There is also a need to demonstrate the 
ability of these candidates to meet the TPP and key characteristics discussed earlier, such as the ability to 
prevent transmission and viremia, early onset of immunity, long lasting immunity after single dose, prevention 
of abortion on challenge etc.  
An area that still needs much more work and focus is the development and implementation of appropriate 
vaccination strategies, or control strategies involving vaccines. Given the fact that the bulk of endemic countries 
do not vaccinate during inter-epidemic periods - and some not even around declared epidemics - calls for more 
solid strategies around vaccination. This should include regional approaches relying on tools such as vaccine 
banks, multi-vaccines, field tools for active surveillance (sentinel animals and field diagnostic assays etc.). There 
are opportunities to pilot such programs at regional level in Africa, building on lessons learned to date. 
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ANNEX 1: Additional data on disease presence and 
incidence 
 
Reports to OIE on RVF: 
 
When different animal health statuses between domestic and wild animal population are provided, the box is 
split in two: the upper part for domestic animals, and the lower part for wild animals.  
RVF in Western Africa: Burkina Faso, Ivory Coast, Mali and Senegal 
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RVF in Eastern Africa:  Ethiopia, Kenya, Rwanda, Tanzania and Uganda 
 
RVF in Southern Africa: Madagascar, Malawi, Mozambique, South Africa and Zambia 
 
